Want to see SE:ALZ full AI Analyst Report?

Alzinova AB (ALZ) Price & Analysis

2 Followers

ALZ Stock Chart & Stats

kr0.82

-kr0.14(-4.96%)

At close: Mar 06 4:00 PM EST

kr0.82

-kr0.14(-4.96%)

Day’s Range― - ―

52-Week Rangekr0.38 - kr2.28

Previous CloseN/A

Volume98.89K

Average Volume (3M)655.64K

Market Cap

kr198.18M

Enterprise Valuekr39.54M

Total Cash (Recent Filing)kr11.38M

Total Debt (Recent Filing)kr800.00K

Price to Earnings (P/E)―

Beta0.19

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding202,640,560

10 Day Avg. Volume664,473

30 Day Avg. Volume655,642

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-2.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.32

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetExtremely low leverage materially reduces near-term solvency and refinancing risk for a pre-revenue biotech. This provides durable financial flexibility to support clinical programs, partnership negotiations, or staged financing rounds without immediate debt pressures, lengthening runway options.

Focused Alzheimer’s R&D PlatformA clear, focused R&D strategy centered on a vaccine-based approach to Alzheimer’s creates durable scientific positioning. Specialization around ALZ-101 concentrates expertise and assets, improving odds of efficient program execution and making the company a clearer partner or licensing target if preclinical/clinical data progress.

Clear Licensing / Partnership PathwayAn explicit business model that prioritizes licensing and partnerships aligns with industry norms for clinical-stage biotech. This durable pathway can unlock non-dilutive or milestone-driven funding, transfer commercialization risk, and accelerate development through established partners if scientific results justify deals.

Bears Say

Revenue Collapse And Persistent LossesNear-zero revenue paired with large, recurring net losses is a persistent structural weakness. Over 2–6 months this implies continued reliance on external capital, negative returns on equity, and potential dilution that can erode investor value and impede long-term program continuity absent clear funding or partnerships.

Sustained Negative Operating And Free Cash FlowConsistently negative OCF and material negative free cash flow indicate structural cash burn from R&D activity. This persistent cash deficit increases financing frequency and execution risk, potentially forcing program delays, downscaling, or unfavorable funding terms that harm long-term development prospects.

Dependence On Financing, No Commercial RevenueA business model reliant on equity/debt financing and grants creates durable funding risk: access and terms vary with markets and milestones. Without commercial products, the company faces ongoing dilution and timing uncertainty that can constrain strategic choices and increase vulnerability to funding cycles.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.38 and its highest was kr2.28 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr198.18M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is Aug 20, 2026 which is in 20 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on May 13, 2026. The company reported -kr0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.056.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 202,640,560 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.704%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.